. 2016 Feb 24;7(17):23227–23238. doi: 10.18632/oncotarget.7594

Table 2. Dose-Escalation Schedule (28-day cycle), Grade 3/4 Toxicities^* and Response.

Dose Level	N	Temsirolimus IV on Days 1, 8, 15, 22	Bevacizumab IV on Days 1, 15	Cetuximab IV on Days 1, 8, 15, 22	SD≥6 months or PR /Total treated	Grade (G) 3/4 Toxicity (N)^*
1	3	5 mg	5 mg/kg	100/75 mg/m²	1/3	G3/4 Neutropenia (1)
2	16	5 mg	10 mg/kg	100/75 mg/m²	5/16	G3 Hypophosphatemia (1) G3 Elevated Aspartate Aminotransferase (1)^Δ G3 Hyperglycemia (3) G3 Hypokalemia (1) G3 Anemia (1) G3 Hyperkalemia (1) G3 Infusion reaction (1)^Δ G3 Vomiting (1) G4 Stomach leak/perforation (1)^Δ
3	2	12.5 mg	2.5 mg/kg	100/75 mg/m²	0/2	G3 Headache (1)^Δ G3 Hypophosphatemia (2) G3 Mucositis (1)^Δ G3 Fatigue (1)^Δ

Adverse events deemed at least possibly related to treatment were graded based on the Common Terminology Criteria for Adverse Events, version 3.0 (CTCAEv3.0)

^Δ

was defined as a dose-limiting toxicity

Abbreviations: N, number of patients

Table 2. Dose-Escalation Schedule (28-day cycle), Grade 3/4 Toxicities* and Response.

Table 2. Dose-Escalation Schedule (28-day cycle), Grade 3/4 Toxicities^* and Response.